Related Experiment Video
Updated: May 16, 2025
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.3K
Device-based therapies for heart failure with preserved ejection fraction.
Ryan Kim1, Veraprapas Kittipibul2,3, Sapna Bhatt4
1Duke University, Durham, NC, USA.
Heart Failure Reviews
|April 3, 2025
Summary
Device therapies show promise for heart failure with preserved ejection fraction (HFpEF), offering new strategies where medical treatments are limited. Ongoing research explores various device types to improve patient outcomes in this complex condition.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Research
Background:
- Heart failure with preserved ejection fraction (HFpEF) is a complex condition with diverse causes and phenotypes.
- Effective medical treatments for HFpEF are limited, leading to high morbidity and mortality.
- Device-based therapies represent a potential advancement for managing HFpEF.
Purpose of the Study:
- To review current device-based therapies for HFpEF.
- To explore devices targeting structural, autonomic, and electrophysiologic mechanisms.
- To discuss the role of remote monitoring in HFpEF management.
Main Methods:
- Review of existing data on device therapies in HFpEF.
- Categorization of devices by mechanism of action.
- Analysis of early clinical trial outcomes.
Main Results:
- Various device types are being investigated for HFpEF.
- Mechanisms include structural, autonomic, and electrophysiologic modulation.
- Remote monitoring devices are also being explored.
Conclusions:
- Early clinical benefits of therapeutic devices in HFpEF are not yet definitive.
- Emerging evidence suggests potential benefits in specific patient subgroups.
- Further research is needed to establish the efficacy of these technologies.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
331
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331
01:22Heart Failure Drugs: β-Blockers
284
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
284
01:22Heart Failure Drugs: Diuretics
298
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298
01:26Heart Failure Drugs: Inotropic Agents
445
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
445
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
110
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
110